Displaying drugs 2251 - 2275 of 3524 in total
AIM-102
AIM-102 is under investigation in clinical trial NCT01501942 (Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma).
Investigational
GCS-100
Investigational
NZ-1002
Investigational
OCU-100
Investigational
PTX-100
Investigational
LX-1004
Investigational
CAN-106
CAN-106 a novel, long-acting monoclonal antibody directed against human complement C5.
Investigational
Racecadotril
Racecadotril has been investigated for the basic science and treatment of Diarrhea, Acute Diarrhea, and Acute Gastroenteritis.
Investigational
Matched Products: … HIDRASEC GRANULOS 10 MG ... RESORCAL 10 MG GRANULADO ... ALPEX RACETRIL 10 MG. GRANULADO …
Borocaptate
Investigational
Methyldiazene
Experimental
(3AS,4R,9BR)-4-(4-HYDROXYPHENYL)-6-(METHOXYMETHYL)-1,2,3,3A,4,9B-HEXAHYDROCYCLOPENTA[C]CHROMEN-8-OL
Experimental
Matched Iupac: … (2R,6S,7R)-7-(4-hydroxyphenyl)-10-(methoxymethyl)-8-oxatricyclo[7.4.0.0^{2,6}]trideca-1(9),10,12-trien …
LLL-3348
The botanical drug product LLL-3348 is a once-daily oral formulation for treatment of chronic stable plaque type psoriasis.
Investigational
Tovinontrine
Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor. Tovinontrine is under investigation in clinical trial NCT04474314 (A Study of IMR-687 in Subjects With Sickle Cell Disease).
Investigational
Matched Description: … Tovinontrine is an orally administered, highly selective phosphodiesterase 9 (PDE9) small molecule inhibitor …
CT-001
Investigational
WL-1002
WL-1002 is developed by Winston Laboratories which is a topical cream formulation of 075% zucapaicin (also known as civamide), for the treatment of pain due to osteoarthritis.
Investigational
BL-1020
BL-1020 is a first in class novel compound for the treatment of schizophrenia. It is being developed by BioLineRx (BioLine).
Investigational
NOX-100
NOX-100 is the new nitric oxide (NO) neutralizing agent being developed by San Diego-based Medinox -- demonstrated its effectiveness and potential as a therapeutic to treat hemorrhagic shock. NOX-100 is the first in a series of proprietary NO neutralizing compounds Medinox is developing to bind and inactivate NO, a simple...
Investigational
VIT-100
VIT-100 was developed by ItherX Pharmaceuticals of San Diego. In preclinical studies, companyl has shown that VIT-100 inhibits the growth of cells taken from multiple keloid biopsies as compared to the same keloidal cells treated with a control. It is believed that similar effects would be seen in cells isolated...
Investigational
PPL-100
Investigational
LTX-109
LTX-109 has been investigated for the treatment of Atopic Dermatitis, Mild Eczema/Dermatoses, and Gram-positive, Skin Infections.
Investigational
SER-100
SER-100 is under investigation in clinical trial NCT01987284 (SER100 in Isolated Systolic Hypertension).
Investigational
STX-100
STX-100 is under investigation in clinical trial NCT01371305 (STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)).
Investigational
EHP-102
Investigational
STX-107
Investigational
Displaying drugs 2251 - 2275 of 3524 in total